Collegium Pharmaceutical, Inc. COLL
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
What this company does
Written from the business description in COLLEGIUM PHARMACEUTICAL, INC's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.
Growth
Revenue compounded at +20.3% a year over the five years to FY2025 — but profit grew slower: net income at +18.6%, earnings per share at +17.9%.
The share count fell from 0.03B to 0.03B — the buyback concentrates the same profit into fewer slices.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity produced 24 cents of profit this year.
The 13-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.8 | 0.6 | 0.6 | 0.5 | 0.3 | 0.3 | 0.3 | 0.3 | 0.0 | 0.0 | ◌ | ◌ | ◌ |
| Operating income $B | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.1 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.1 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | −0.0 | −0.1 | 0.0 | 0.0 | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Net income $B | 0.1 | 0.1 | 0.0 | −0.0 | 0.1 | 0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | 0.3 | 0.2 | 0.3 | 0.1 | 0.1 | 0.1 | 0.0 | 0.2 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | 1.73 | 1.86 | 1.29 | −0.74 | 1.86 | 0.76 | −0.68 | −1.19 | −2.47 | −3.88 | −1.48 | −22.72 | −4.06 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | 23.7 | 32.6 | 24.7 | −12.6 | 36.8 | 19.6 | −25.4 | −40.0 | −62.7 | −85.6 | — | — | — |
| Shares out B | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.00 | 0.00 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 10 of the 13 fiscal years we could check. 14 checks were skipped: the balance sheet is not tagged before 2014. Nine checks were skipped: revenue is not tagged before 2016. Six checks were skipped: EPS is not tagged before 2013.